Piperacillin |
Catalog No.GD20400 |
Products are for research use only. Not for human use. We do not sell to patients.
Cas No.: 61477-96-1
Sample solution is provided at 25 µL, 10mM.
Piperacillin (12.5 渭g/mL, 24h) inhibits 92% of isolates of Pseudomonas aeruginosa, 82% of Serratia marcescens, 73% of Escherichia coli, 61% of Klebsiella spp, and 42% of Enterobacter spp, most Proteus spp. were extremely susceptible. Piperacillin fails to inhibit the growth of gram-negative bacilli when large inocula were used (minimum inhibitory concentration > 25 渭g/ml) [2].
Piperacillin (100 mg/kg, i.v., 4 times a day, 5 d) in combination with Tazobactam (12.5 mg/kg, i.v., 4 times a day, 5 d) prolongs survival in mice with low inoculum of K. pneumoniae[3].
[1]. Fu KP, et al. Piperacillin, a new penicillin active against many bacteria resistant to other penicillins. Antimicrob Agents Chemother. 1978锛?3(3):358-67.
[2]. Bodey GP, et al. Piperacillin: In Vitro Evaluation. Antimicrob Agents Chemother. 1978锛?4(1):78-87.
[3]. Harada Y, et al. In vitro and in vivo activities of piperacillin-tazobactam and meropenem at different inoculum sizes of ESBL-producing Klebsiella pneumoniae. Clin Microbiol Infect. 2014锛?0(11):O831-9.
Average Rating: 5
(Based on Reviews and 30 reference(s) in Google Scholar.)GLPBIO products are for RESEARCH USE ONLY. Please make sure your review or question is research based.
Required fields are marked with *